Despite the widespread impact of osteoporosis and osteoarthritis, treatment options remain limited. Most osteoporosis therapies focus on slowing bone loss, while no approved treatments can effectively halt or reverse osteoarthritis.

Researchers from the University of California have now identified a promising molecule, CCN3—also known as the Maternal Brain Hormone—that could transform the treatment of bone and cartilage disorders. In a study published in Nature, scientists from UC Davis Health and UC San Francisco found that CCN3 significantly enhances bone density, strength, regeneration, and repair.

Unlike current osteoporosis medications that mainly prevent further bone loss, CCN3 activates skeletal stem cells to stimulate the formation of new bone. In preclinical studies, the hormone accelerated fracture healing and demonstrated potential for cartilage regeneration, opening new possibilities for treating osteoporosis, fractures, and osteoarthritis.

The discovery stems from over two decades of research into hormone signaling and bone biology. Scientists identified CCN3 as a brain-derived factor released by the hypothalamus that naturally helps protect bone during breastfeeding, when calcium demands are high. This breakthrough reveals a previously unknown brain-to-bone communication pathway that regulates skeletal health.

Researchers are now investigating how CCN3 can be developed into a new anabolic therapy for osteoporosis and cartilage repair. Future applications may help prevent bone loss, accelerate fracture recovery, and regenerate damaged joint cartilage, offering hope to millions affected by age-related musculoskeletal diseases.

Source: https://health.ucdavis.edu/news/headlines/scientists-identify-hormones-that-may-offer-hope-for-osteoporosis-and-osteoarthritis-patients/2026/06